[8-K] Lucid Diagnostics Inc. Reports Material Event

Rhea-AI Filing Summary

Lucid Diagnostics Inc. announced it furnished a press release reporting financial results and a business update for the fiscal quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into this Form 8-K. The company disclosed that the information under Items 2.02 and 7.01, including the exhibit, is furnished and shall not be deemed "filed" under the Exchange Act for purposes of Section 18, nor incorporated by reference in other filings except by specific reference. The filing identifies the registrant as Lucid Diagnostics Inc., trading as LUCD on The Nasdaq Stock Market, and indicates the company qualifies as an emerging growth company.

Positive

• Company furnished a press release announcing financial results and a business update for the quarter ended June 30, 2025
• Press release attached as Exhibit 99.1, providing a direct source for investors to review results and updates
• Registrant confirmed Nasdaq listing under the symbol LUCD and identified as an emerging growth company

Negative

• None.

Insights

Securities Analyst

TL;DR This 8-K furnishes an earnings press release and a business update; the disclosure is routine and informational.

The filing notifies investors that Lucid Diagnostics has issued a press release with quarter-end financial results and a business update, attached as Exhibit 99.1. Because the company specifies the disclosures are "furnished" and not "filed," the legal incorporation by reference is limited. For analysts, the 8-K itself contains no financial metrics; investors must review the attached press release for material performance data. The filing confirms LUCD’s Nasdaq listing and emerging growth company status, which may affect certain reporting and compliance timelines.

Corporate Governance Expert

TL;DR The Form 8-K documents routine disclosure practice; legal treatment of the press release is explicitly limited.

The company follows standard disclosure protocol by furnishing — rather than filing — the press release and business update, explicitly stating limited incorporation by reference. This approach limits Section 18 liability for the content of the press release unless later expressly referenced in another filing. The 8-K itself conveys no substantive operational or financial detail; governance stakeholders should review Exhibit 99.1 to assess any changes to strategy, results, or forward-looking statements.

false 0001799011 0001799011 2025-08-13 2025-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 13, 2025

LUCID DIAGNOSTICS INC.

(Exact Name of Registrant as Specified in Charter)

Delaware		001-40901		82-5488042
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

360 Madison Avenue, 25th Floor, New York, New York		10017
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (917) 813-1828

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share		LUCD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2025, Lucid Diagnostics Inc. (the “Company”) issued a press release announcing financial results for its fiscal quarter ended June 30, 2025 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

The disclosure set forth under Item 2.02 is incorporated herein by reference.

The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.		Description
99.1		Press release.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 13, 2025	LUCID DIAGNOSTICS INC.
	By:	/s/ Dennis McGrath
		Dennis McGrath
		Chief Financial Officer

3

FAQ

What did Lucid Diagnostics (LUCD) disclose in this 8-K?

The company furnished a press release reporting financial results and a business update for the fiscal quarter ended June 30, 2025, attached as Exhibit 99.1.

Is the press release in the 8-K considered "filed" with the SEC?

No. The company states the information under Items 2.02 and 7.01, including the exhibit, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.

Where does Lucid Diagnostics trade and what is the ticker?

Lucid Diagnostics trades on The Nasdaq Stock Market under the symbol LUCD.

Does the filing indicate Lucid Diagnostics is an emerging growth company?

Yes. The filing indicates the registrant has marked that it is an emerging growth company.

Where can I find the detailed financial results referenced in the 8-K?

The detailed financial results and business update are contained in the press release attached to the 8-K as Exhibit 99.1.